Joseph Errico - Ondine Biomedical Chief Officer
| OBI Stock | 8.25 0.12 1.48% |
Executive
Joseph Errico is Chief Officer of Ondine Biomedical
| Age | 54 |
| Address | 1100 Melville Street, Vancouver, BC, Canada, V6E 4A6 |
| Phone | 604 669 0555 |
| Web | https://ondinebio.com |
Joseph Errico Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Errico against Ondine Biomedical stock is an integral part of due diligence when investing in Ondine Biomedical. Joseph Errico insider activity provides valuable insight into whether Ondine Biomedical is net buyers or sellers over its current business cycle. Note, Ondine Biomedical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ondine Biomedical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Errico over two months ago Acquisition by Joseph Errico of 100000 shares of Electrocore LLC at 0.5578 subject to Rule 16b-3 | ||
Joseph Errico over three months ago Acquisition by Joseph Errico of 25000 shares of Electrocore LLC at 0.3301 subject to Rule 16b-3 | ||
Joseph Errico over six months ago Acquisition by Joseph Errico of 100000 shares of Electrocore LLC at 0.3333 subject to Rule 16b-3 |
Ondine Biomedical Management Efficiency
The company has return on total asset (ROA) of (1.5971) % which means that it has lost $1.5971 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.8559) %, meaning that it generated substantial loss on money invested by shareholders. Ondine Biomedical's management efficiency ratios could be used to measure how well Ondine Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ondine Biomedical's Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 7.7 M, whereas Non Currrent Assets Other are forecasted to decline to about 33.2 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| BCom BComm | GoldMining | 58 | |
| Kenneth PGeo | McEwen Mining | N/A | |
| Lina Vilca | Southern Copper Corp | 63 | |
| LLM CFA | McEwen Mining | 53 | |
| Sapan Ghai | GreenX Metals | N/A | |
| Raul Ruisanchez | Southern Copper Corp | 66 | |
| Jeffrey Chan | McEwen Mining | 38 | |
| Alastair Still | GoldMining | 52 | |
| Michael Meding | McEwen Mining | 50 | |
| Stephen PGeo | McEwen Mining | 65 | |
| Carmen Diges | McEwen Mining | 53 | |
| YongJae LLB | GoldMining | N/A | |
| Tim Berryman | Medical Properties Trust | N/A | |
| Katherine Arblaster | GoldMining | N/A | |
| Andrew CFA | Medical Properties Trust | N/A | |
| Julian Psihas | Southern Copper Corp | 56 | |
| Jamey Ramsey | Medical Properties Trust | N/A | |
| George Bracken | National Beverage Corp | 79 | |
| Victor Pedraglio | Southern Copper Corp | N/A | |
| AGIA BCom | GreenX Metals | N/A | |
| MAusIMM BSc | GreenX Metals | N/A | |
Management Performance
| Return On Equity | -6.86 | ||||
| Return On Asset | -1.6 |
Ondine Biomedical Leadership Team
Elected by the shareholders, the Ondine Biomedical's board of directors comprises two types of representatives: Ondine Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ondine. The board's role is to monitor Ondine Biomedical's management team and ensure that shareholders' interests are well served. Ondine Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ondine Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nikita Parkhaev, Company Secretary | ||
| CFA CFA, CEO Founder | ||
| Elaine CPA, Corporate Controller | ||
| Vipul Shah, VP CFO | ||
| Simon Sinclair, Chief Director | ||
| Joseph Errico, Chief Officer | ||
| Mike Long, VP Operations | ||
| CIMA CPA, Interim Officer | ||
| Nicolas Loebel, CTO President | ||
| Thomas Dawson, Sr Devel | ||
| William Kanz, Senior Operations | ||
| Angelika Vance, Vice Communications | ||
| Matt Ross, Vice Marketing | ||
| Nikita Parkev, VP Secretary |
Ondine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ondine Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.86 | ||||
| Return On Asset | -1.6 | ||||
| Operating Margin | (9.12) % | ||||
| Current Valuation | 24.29 M | ||||
| Shares Outstanding | 300.46 M | ||||
| Shares Owned By Insiders | 46.89 % | ||||
| Shares Owned By Institutions | 14.10 % | ||||
| Price To Book | 2,295 X | ||||
| Price To Sales | 15.17 X | ||||
| Revenue | 1.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ondine Stock
Ondine Biomedical financial ratios help investors to determine whether Ondine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ondine with respect to the benefits of owning Ondine Biomedical security.